I am a
Home I AM A Search Login

Papers of the Week


Papers: 29 Jan 2022 - 4 Feb 2022


Human Studies


2022 Jan 29


J Headache Pain


23


1

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.

Authors

Tao X, Yan Z, Meng J, Wang W, Dai Q, Zhou Q, Wang Z, Wang Z
J Headache Pain. 2022 Jan 29; 23(1):19.
PMID: 35093013.

Abstract

Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has been initiated for the prophylactic treatment of migraine. However, there is no comprehensive literature to study the efficacy and safety of atogepant for the treatment of migraine. In this article, we present a meta-analysis of the available studies.